Congress orders study on drug prices and domestic medicine making

What it does

The bill tells the Centers for Medicare and Medicaid Services to study drug prices. It asks how to help U.S. companies make more medicine ingredients. The study may suggest price floors to protect domestic makers. It may suggest picking U.S.-made ingredients for Medicare and Medicaid. The bill asks for a report but does not order changes now.

Who it affects

Citizens could benefit if the U.S. makes more medicine ingredients. Drug costs might go up if price floors raise government payments. Domestic medicine makers and ingredient producers stand to gain.

One thing to notice

This is a study only, not a law that changes anything yet. What happens depends on what the Centers for Medicare and Medicaid Services finds.

From the analysis of the bill text, linked under Primary records below.

Where it stands

1 cosponsor: 1 Republicans.

• Aug 6, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Aug 6, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Words to know

• Centers for Medicare and Medicaid Services — The federal agency that runs Medicare and Medicaid health programs.
• price floors — A lowest price that sellers must charge; prices cannot go below it.